Knee Cartilage Implant Beats Standard Surgery With 5-Year Durability Data
A regenerative knee implant outperformed standard surgical care on pain, mobility, and function across five years — including in osteoarthritis patients.
Summary
For people with significant knee cartilage damage who aren't yet candidates for full joint replacement, a new implant called AGILI-C may offer a meaningful alternative. Five-year trial data published in the American Journal of Sports Medicine show the aragonite-based scaffold outperformed standard surgical care on every measured outcome — pain, mobility, and daily function. Crucially, it worked equally well in patients with mild to moderate osteoarthritis, a group typically excluded from cartilage repair trials. The implant is already FDA-approved in the US, and a new reimbursement code taking effect in January 2027 could significantly expand patient access. This addresses a long-standing treatment gap for active adults caught between minor procedures and full knee replacement.
Detailed Summary
Millions of people live with knee cartilage damage severe enough to limit daily life but not severe enough to qualify for total joint replacement. This in-between zone has long lacked reliable solutions — until now. Five-year clinical data on the AGILI-C implant from Smith+Nephew suggest that a regenerative approach may finally fill that gap with durable, measurable results.
The AGILI-C implant is made from aragonite, a naturally occurring mineral, and functions as a biodegradable scaffold inserted into the damaged joint area. Rather than scraping or drilling the cartilage as standard procedures do, it provides a structural framework that supports the body's own regeneration of cartilage and underlying bone. The philosophy shifts from symptom management toward biological restoration.
In the trial, published in the American Journal of Sports Medicine, AGILI-C patients showed twice the reduction in pain scores compared to standard care. Improvements in mobility and daily function were sustained across all measured time points over five years, with fewer treatment failures. Notably, outcomes were comparable between patients with and without osteoarthritis — a finding that significantly broadens the implant's clinical relevance.
The osteoarthritis finding is particularly important. This patient population is large, historically underserved, and routinely excluded from cartilage repair trials. Experts from Weill-Cornell and Humanitas Research Hospital described the results as providing a dependable, evidence-based option for patients previously stuck in medical limbo.
Practically, the implant is already FDA-approved with broad patient eligibility. A Category I CPT reimbursement code set for January 2027 will likely accelerate real-world adoption. Caveats include the industry-sponsored nature of the trial and the need for independent replication. Still, for health-conscious adults managing joint health and mobility as a longevity priority, this represents a credible and timely development.
Key Findings
- AGILI-C implant produced twice the pain reduction versus standard surgical care over five years
- Mobility and function improvements were sustained across all measured time points through year five
- Implant performed equally well in patients with and without mild-to-moderate osteoarthritis
- FDA-approved with broad eligibility, expanding access beyond existing cartilage repair techniques
- A new CPT reimbursement code in January 2027 is expected to accelerate clinical adoption
Methodology
This is a news report summarizing a five-year randomized controlled trial published in the American Journal of Sports Medicine, a peer-reviewed orthopedic journal. The study was conducted by Smith+Nephew, the implant's manufacturer, introducing potential industry bias. Independent expert commentary is included but primary trial data should be reviewed for full methodology.
Study Limitations
The trial is industry-sponsored by Smith+Nephew, which warrants scrutiny of outcome reporting and patient selection. Independent replication in non-industry settings has not yet been reported. The article does not detail sample size, dropout rates, or adverse event profiles, all of which are necessary for full clinical evaluation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.